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Introduction  
 
Envenoming resulting from snakebites is an important public health problem in 
many tropical and subtropical countries. Snakebites cause considerable morbidity 
and mortality worldwide. Venomous snakes are found throughout most of the 
world (including many oceans), except for a few islands, frozen environments, and 
high altitudes(18).  The highest burden exists in South Asia, Southeast Asia, and 
sub-Saharan Africa. Populations in these regions experience high morbidity and 
mortality because of poor access to health services, which are often suboptimal, 
and, in some instances, a scarcity of antivenom, which is the only specific 
treatment. 
 Recent estimates suggest that worldwide, venomous snakes cause “5.4 
million bites, about 2.5 million envenomings and over 125,000 deaths 
annually”(20), “more than 3 million bites per year resulting in more than 150,000 
deaths”(21), or “several million bites and envenomings annually with tens of 
thousands of deaths”(22). Hospital mortality data are well known to underestimate 
overall mortality due to snakebites(25)
Of the 3,000 or so snake species that exist in the world, about 600 are 
venomous. In the country, approximately 95% of the mortality is attributable to 
bites by the cobra (Naja naja), Russell’s viper (Daboia russelii), common krait 
(Bungarus caeruleus). The principal effects of envenomation with snake toxins are 
related to neurotoxicity, nephrotoxocity, myotoxicity, cardiotoxicity, 
coagulopathy, vascular endothelial damage and local reactions.  
Snake venom is not a single toxin but a complex mixture of several 
components, including enzymes, polypeptide toxins, non-toxic proteins, 
carbohydrates, metals, lipids, free amino acids, nucleotides and bionic amines. 
Neurotoxins of snake venom seem to affect various sites of neuromuscular system 
Snake venom neurotoxins that bind to acetylcholine receptor sites on the motor 
endplate produce effects similar to those of curare and myasthenia gravis. Another 
group of neurotoxins with phospholipase A2 bind presynaptically, thereby 
depressing transmitter release, and are completely resistant to anticholinesterases. 
Respiratory muscle weakness is a potentially fatal manifestation of snake bite. 
Because most snakebite victims are young(19), the economic impact of their 
disability is considerable. Despite the scale of its effects on populations, snakebite 
has not received the attention it deserves from national and international health 
authorities, and may therefore be appropriately categorized as a neglected tropical 
disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aims and Objectives 
 
• To define the snakes causing neurotoxicity, 
• To analyse the demographic data of the patients admitted with neurotoxic 
snake bite 
• To study the  spectrum of neurological manifestations following 
envenomation,  
• To identify the variations in the clinical presentation in patients with 
associated hemotoxicity and local cellulitis  
• To study the pattern of electrophysiologic changes in the Nerve conduction 
studies and the correlation with outcome 
• To study the  disease course and outcome among patients admitted with 
neurotoxic snake bite 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Review of Literature 
 
Snake venoms can be broadly categorized into many types,:  
 1) Hemotoxic Venoms            
These venoms attack the cardiovascular system, circulatory system and 
muscle tissues, thus directly leading to heart failures. The 'crotalus adamanteus', 
notoriously known as the western diamondback rattle snake, uses this deadly 
venom to make it's prey more pliable(27). This venom causes the poisoning of 
blood and affects the blood clotting mechanism to such a grave extent, that the 
victim can die of internal bleeding. Usually, no pain nor any other symptoms can 
be observed for almost 1-3 hours (sometimes even 8). The effects of this venom 
can be seen as lethargy, headaches, nausea, vomiting, etc.. It is these venoms that 
usually cause excessive (and hideous) scarring, gangrene and permanent or 
temporary loss of motor skills. 
  
2) Neurotoxic Venoms  
         These venoms go after the central nervous system and brain. They often 
result in respiratory paralysis . Their effect can range between mild seizures to 
death. Cobras, mambas, sea snakes, kraits and coral snakes are known to possess 
this venom. The king cobras (ophiophagus hannah) are the most infamous carriers 
of this venom. Neurotoxic venom is essentially nerve destroying. Hence, one can 
see speech and swallowing difficulties, drooling, difficulty in breathing, 
respiratory arrests, convulsions and sometimes even prolonged unconsciousness in 
the victims. The milder symptoms are dizziness, tunnel vision, blurred vision and 
increased sweating. This venom causes a very fast degeneration of the synaptic 
nerves and this is the reason for the blockage of nerve impulses sent to and from 
the brain to the muscles(26).
 
 3) Cytotoxic Venoms   
          This is a milder venom that generally causes only localized symptoms at the 
location of the bite. This is a cell destroying venom that destroys everything in it's 
path - blood vessels, cells and tissues. The symptoms of the invasion of this venom 
are generally seen around 10-15 minutes after the snake encounter . The results are 
generally localized pain accompanied by severe swelling and bleeding.. This 
venom causes blue/black spotting due to limited blood circulation(26). 
 
4) Myotoxic Venoms            
This venom is found in the 'bothrops moojeni' snakes, commonly known as 
the Brazillian lancehead snakes. This venom is known to cause muscular necrosis. 
Myotoxic venom contains peptides that destroy the muscle fiber proteins and 
result in myonecrosis (muscle destruction). In the very later stages of the spread of 
this venom, the muscle proteins enter the blood stream ultimately result in renal 
failure.  
 
 
Hemotoxic Snake Bite 
          Hemostasis is a balance of two opposing forces: clot formation and 
dissolution. Appropriate clotting is essential at the site of a wound in order to 
maintain hemostasis, however clotting away from the site of a wound must be 
minimized in order to prevent  life-threatening thrombotic events(27). Regulation of 
clotting involves a series of zymogen conversions with extensive use of co-factors. 
Each stage involves the conversion of a precursor to an active form, which then is 
involved in the activation of a factor in the next stage of the cascade. The ultimate 
goal is the activation of the protease thrombin with the subsequent conversion of 
fibrinogen to fibrin for use in clot formation. 
  
 Effects Of Venoms Upon Hemostasis            
Venoms often have profound effects upon blood coagulation, acting 
directly upon important clotting factors either by inappropriate activation or 
through prevention of activation. The same net effect (i.e. inability to stop 
bleeding) may be produced by dramatically different mechanisms allowing for the 
selective use of venom or venom components to address a specific deficiency in 
blood chemistry. As blood coagulation therapies or diagnostic tools, the most 
important snake venom components have been homeostatic or antithrombotic 
agents(27). 
  
  
 Russell's Viper Venom            
The use of snake venoms as homeostatic agents is based upon early 
observations of the potent coagulative properties of snake venoms, the Russell's 
viper (Daboia russelli) in particular gaining early use as a treatment of 
hemophilia. The mechanism of action of D. russelli venom is in the activation of 
the factors V, X, IX, as well as Protein C (27). While D. russelli venom is no longer 
used as a therapeutic agent, it still is used as a diagnostic agent to determine 
deficiencies in clotting factor X.  
 
Prothrombin Activators 
           In addition to measurement of factor X by D. russelli venom, other blood 
chemistry research or diagnostic uses of snake venoms utilizes the enzymes 
affecting the coagulation cascade, such as prothrombin activators to measure 
factor V levels in patients' blood.  
 Prothrombin activators found in snake venoms can be divided into four groups:            
Group I convert prothrombin to meizothrombin with activity insensitive to 
the presence of the non-enzymatic prothrombinase complex cofactors (CaCL2, 
factor V and phospholipids) 
Group II and III activators are able to cleave both peptide bonds in 
prothrombin essential for the conversion of prothrombin to thrombin, the 
difference between the II and III being that the converting activity of II is strongly 
stimulated by phospholipids and factor Va in the presence of calcium while III is  
only stimulated by CaCl2 and phospholipid (27) 
          Group IV activators are proteases that cleave prothrombin into non-active 
precursor forms of thrombin rather than converting prothrombin into the 
enzymatically active products. 
 
Thrombin-Like Enzymes 
          Thrombin-like enzymes, such as those abundantly found in viper venoms, 
are used to determine the levels of fibrinogen in a plasma sample by converting 
fibrinogen to fibrin and the levels of fibrin subsequently measured against a 
baseline. One of these serine proteases, batroxobin from the Central American pit 
viper Bothrops moojen, (26) is quite useful in its ability, unlike circulating 
prothrombin, to form clots even in the presence of heparin. This allows for a 
patient's plasma to be monitored for levels of fibrinogen even whilst undergoing 
heparin therapy. Consequently, these studies concluded that batroxobin is quite 
useful not only as a diagnostic agent but also possibly as a direct therapeutic agent. 
 
Neurotoxic Snake Bite 
           The nervous system functions by conducting an electrical signal or impulse 
along the length of the nerve and transmitting it across a junction (called the 
synaptic cleft) to another nerve or to a muscle fiber. When a nerve impulse reaches 
the terminus of the nerve, an influx of ions promotes the release of vesicles 
containing a neurotransmitter such as acetylcholine, allowing this messenger 
molecule to diffuse across the synaptic cleft and bind to specific receptors.  
 Ion Channels          
Many of the important binding sites of the nervous system, such as ion 
channels, were elucidated using bacterial neurotoxins. Channels for the ions Na+ 
and Ca2+ play crucial roles in the transmission of a nerve impulse and are found 
pre- and post-synaptically for sodium and presynaptically only for calcium 
channels. 
           Na+ channels are made up of four transmembrane loops with repeating 
binding sites. The neuronal sodium channels are important during the initial phase 
of action potential due to the voltage-sensitive production of an inward movement 
of Na+ and a rapid depolarization from the resting potential continuing to a slight 
positive overshoot(28). In addition, Na+ channels play a major role in determining 
the excitability of central neurons as revealed through the bacterial toxins 
tetrodotoxin and saxitoxin being selective towards particular channel subtypes. 
  Thus, sodium channels are often described as being tetrodotoxin-sensitive or 
saxitoxin-sensitive if toxin binding interferes with the nerve impulse(29). By 
preventing the agonist-induced conformational change in the receptor ion channel 
required for the influx of sodium that is essential for membrane depolarization, 
these toxins inhibit neurotransmitter action and induce paralysis. 
 
 
 .  
Fig 1. Basic structure of the neuromuscular junction showing the major channels 
and structures involved in nerve transmission.  
  
 
     
  Ca2+ channels, while not directly involved in the conductance of a nerve 
impulse, function to prolong the depolarization through the inward movement of 
Ca2+ thus causing the release of acetylcholine vesicles. Several calcium channel 
subtypes (L, N, P/Q, R and T) abound the nerve terminus, being differentiated 
through their sensitivity to different toxins. The P-type calcium channel, for 
example, was specifically characterized by its sensitivity towards the spider toxin 
omega-agatoxin(28)(29). 
           Upon mobilization by the influx of Ca2+ through the calcium channels, the 
acetylcholine containing vesicles fuse with the membrane and exocytotically 
release their contents into the synaptic cleft and rapidly diffuse. Interference with 
the release of acetylcholine produces flaccid paralysis while increased release 
causes severe cramping of muscles. The toxins from the Clostridium bacteria are 
representative of the type that interferes with the release of acetylcholine. 
Botulism bacteria specifically causing flaccid paralysis through targeting the 
cholinergic motor nerve endings while the tetanus bacteria selectively cause 
spastic paralysis by targeting spinal neurons and causing an increase of 
acetylcholine release. 
  
 Acetylcholine Receptors (AchR)           
Acetylcholine has two modes of action, a nicotine-like (nicotinic) or a 
muscarine-like (muscarinic) action, with the former blocked by curare and the 
later by atropine. Nicotinic acetylcholine receptors are found primarily at 
neuromuscular junctions while muscarinic acetylcholine receptors are found 
primarily in the central nervous system. Functionally the two receptors are also 
different, nicotinic AChRs are ligand-gated ion channels while muscarinic AChRs 
are part of a larger class of G-protein coupled receptors(32). This larger class 
utilizes the full-power of the intracellular secondary messenger system which 
involves an increase of intracellular Ca2+ . 
   
 Nicotinic Acetylcholine Receptors (nAChR)          
 Binding by two molecules of acetylcholine to the nicotinic AChR causes a 
conformational change resulting in the formation of an ion pore. This produces a 
rapid increase in cellular permeability of Na+ and Ca2+ ions, depolarization and 
excitation, resulting in muscular contraction(33). Receptor subunits are either alpha 
(alpha2 - alpha9) or beta (beta2 - beta5) types, which leads to quite a number of 
potential combinations but the alpha-subunit is always present in two identical 
copies as these are the sites to which acetylcholine binds. The alpha-subunits also 
determine the binding sites through interaction with the other subunits. 
Neurotoxins targeting this site reversibly block the opening and prevent 
acetylcholine from forming a pore and allowing cations to pass through. 
           Neuronal nicotinic acetylcholine receptors (nnAChR) have been classified 
into two groups based on responses to the snake venom toxin alpha-bungarotoxin 
(BuTX)(35), being either alpha-BuTX-sensitive or insensitive. Alpha-BuTX-
sensitive receptors are composed of alpha7, alpha8 and/or alpha9 subunits while 
alpha-BuTX -insensitive receptors are composed of alpha2, alpha3, or alpha4 
subunits with beta2, beta4 and/or alpha5 subunits. 
 
Muscarinic Acetylcholine Receptors 
          Muscarinic receptors are found in the central nervous system synapses 
rather than at the neuromuscular junction, as is the case with nicotinic 
acetylcholine receptor specific toxins. Muscarinic receptors are involved in a large 
number of physiological functions including heart rate and force, contraction of 
smooth muscles and the release of neurotransmitters. Molecular cloning has 
determined five subtypes of muscarinic receptors, based on pharmacological 
activity they have been broken up into M1-M5. All five subtypes are found in the 
central nervous system while M1-M4 are also scattered widely through a myriad 
of tissues. M1, M3 and M5 receptors cause the activation of phospholipase C, 
generating two secondary messengers (IP3 and DAG) eventually leading to an 
intracellular increase of Ca2+, while M2 and M4 inhibit adenylate cyclase thus 
decreasing the production of the second messenger cAMP. Importantly, activation 
of the M2 receptor in the heart mediates the closing of calcium channels to reduce 
the force and rate of contraction. Ligand binding to the receptor causes a poorly 
understood conformational change that mediates the association with and 
activation of an intracellular G-protein. This G-protein converts GTP to GDP 
resulting in the disassociation of the activated G-protein allowing this enzyme to 
catalyze intracellular events. 
 Structure of snake neurotoxins  
  The venom from many snakes contain toxins that can bind to each type of 
receptor: the a-bungarotoxins act primarily on nicotinic AchRs at the 
neuromuscular junction, the k-bungarotoxins act primarily on nicotinic AchRs in 
neuronal tissue, and there are also muscarinic AchR-binding toxins(35).  These 
toxins show almost irreversible binding to the receptors, competitively inhibiting 
acetylcholine binding and, consequently, inhibiting the acetylcholine-induced 
electrical response.  Both a- and k-bungarotoxins are three-finger toxins, their 
characteristic ‘3-finger’ structure being determined by disulphide bonds(28)(29).  
This 3-finger fold allows for variation in structure, which can alter the function 
and selectivity of molecular targets.  Evolutionary divergence has given rise to 
over 100 other post-synaptic a-neurotoxins found in Elapidae and Hydrophiidae, 
which may be related to the 3-finger proteins of vertebrates that play a significant 
role in cell-cell adhesion. 
 Other bungarotoxins 
             b-Bungarotoxin is much more lethal than either a- or k-bungarotoxin(34).  b-
Bungarotoxin is a pre-synaptic toxin that acts on the (pre-synaptic) motor nerve 
terminals to block the release of acetylcholine.  The action of b-bungarotoxin is 
complex.  It has phospholipase A2 activity(30)  which functions to hydrolyse 
phosphatidylcholine, in this case the phospholipids in the nerve membrane.  Yet b-
bungarotoxin displays both phospholipase-dependent and –independent 
activities(31).  b-Bungarotoxin is thought to bind to and block Shaker-type 
potassium channels; the subsequent block of transmitter release is probably due to 
phospholipase A2-mediated destruction of the nerve terminal.  Animals die as a 
consequence of respiratory failure.   
Other toxins 
Acetylcolinesterase (AchE) plays a key role in cholinergic nerve 
transmission, acting to breakdown acetylcholine to choline and acetate(32), which is 
important in controlling a receptor’s response.  Snake venom makes use of AChE 
to breakdown any neurotransmitter that might compete with a- or k-bungarotoxin 
for binding to AchRs.  Venom AChE contains an additional exon over endogenous 
AChE, which generates a soluble form of the enzyme that is suitable for its 
venomous use(33). 
Venom is an abundant source of nerve growth factor (NGF)(49), which 
induces neurite outgrowth.  Venom NGF is often less potent than mammalian 
NGF, a family of neurotrophic factors that regulate the survival and differentiation 
of neurons(47).  Venom NGF acts as a low-potency agonist of TrkA-receptors, 
thereby competing for binding with endogenous NGF(48), affecting the survival of 
cholinergic neurons.  
Competitive binding by the potent venoms of many animals produces 
interference of the binding of acetylcholine to the receptors resulting in flaccid 
paralysis. 
 
 
Clinical Features  
A proportion of patients bitten by venomous snakes (between <10% to 
>60%), depending on the species, will develop minimal or no signs of toxic 
symptoms (envenoming) despite having puncture marks which indicate that the 
snake’s fangs have penetrated the skin.  
Fear and effects of treatment, as well as the snake’s venom, contribute to 
the symptoms and signs. Even patients who are not envenomed may feel flushed, 
dizzy and breathless, with constriction of the chest, palpitations, sweating and 
acroparaesthesiae(26). Tight tourniquets may produce congested and ischaemic 
limbs; local incisions at the site of the bite may cause bleeding and sensory loss; 
and herbal medicines often induce vomiting.    
   The earliest symptoms directly attributable to the bite are local pain and 
bleeding from the fang punctures, followed by pain, tenderness, swelling and 
bruising extending up the limb, lymphangitis and tender enlargement of regional 
lymph nodes. Early syncope, vomiting, colic, diarrhoea, angio-oedema and 
wheezing may occur in patients bitten by European Vipera, Daboia russelii, 
Bothrops sp, Australian Elapids and Atractaspis engaddensis. (26)Nausea and 
vomiting are common symptoms of severe envenoming.  
 
 
 
 
Types of bites  
Elapidae (cobras, kraits, mambas, coral snakes and Australian venomous 
snakes)  
Bites by kraits, mambas, coral snakes and some cobras (e.g., Naja haje and 
N. nivea) produce minimal local effects, whereas bites by African spitting cobras 
(N. nigricollis, N. mossambica, etc.) and Asian cobras (N. naja, N. kaouthia, N. 
sumatrana, etc.) cause tender local swelling which may be extensive, blistering 
and superficial necrosis. 
Early symptoms of neurotoxicity before there are objective neurological 
signs include vomiting, “heaviness” of the eyelids, blurred vision, fasciculations, 
paraesthesiae around the mouth, hyperacusis, headache, dizziness, vertigo, 
hypersalivation, congested conjunctivae and “gooseflesh”. Paralysis starts as 
ptosis and external ophthalmoplegia appearing as early as 15 minutes after the 
bite, but sometimes delayed for ten hours or more. Later the face, palate, jaws, 
tongue, vocal cords, neck muscles and muscles of deglutition become 
progressively paralysed. Respiratory failure may be precipitated by upper airway 
obstruction at this stage, or later after paralysis of intercostal muscles, diaphragm 
and accessory muscles of respiration. Neurotoxic effects are completely reversible, 
either acutely in response to antivenom or anticholinesterases (e.g., following bites 
by Asian cobras, some Latin American coral snakes-Micrurus, and Australian 
death adders-Acanthophis) or they may wear off spontaneously in one to seven 
days.  
 Feature Cobras Kraits Russells 
Viper 
Saw 
Scaled 
Viper 
Hump 
Nosed 
Viper 
Local Pain/ Tissue 
Damage 
YES NO YES YES YES 
Ptosis/ Neurological 
Signs 
YES YES YES! NO NO 
Haemostatic 
abnormalities 
NO NO! YES YES YES 
Renal Complications NO NO YES NO YES 
Response to 
Neostigmine 
YES NO? NO? NO NO 
Response to ASV YES YES YES YES NO 
 
Table 1 Clinical Features of bites by various snake species 
    
   Envenoming by Australian snakes causes early vomiting, headache and 
syncopal attacks, neurotoxicity, haemostatic disturbances and, with some species, 
ECG changes, generalized rhabdomyolysis and kidney failure. Painful 
enlargement of regional lymph nodes suggests impending systemic envenoming, 
but local signs are usually absent or mild except after bites by Pseudechis sp.  
  Venom ophthalmia caused by “spitting” elapids  
Patients “spat” at by spitting elapids experience intense pain in the eye, 
conjunctivitis, blepharospasm, palpebral oedema and leucorrhoea. Corneal 
erosions are detectable in more than half the patients spat at by N. nigricollis. 
Rarely, venom is absorbed into the anterior chamber, causing hypopyon and 
anterior uveitis. Secondary infection of corneal abrasions may lead to permanent 
blinding opacities or panophthalmitis.  
 
 Viperidae (vipers, adders, rattlesnakes, lance-headed vipers, moccasins and pit 
vipers)  
Local envenoming is relatively severe. Swelling may become detectable 
within 15 minutes but is sometimes delayed for several hours. It spreads rapidly 
and may involve the whole limb and adjacent trunk. There is associated pain and 
tenderness in regional lymph nodes. Bruising, blistering and necrosis may appear 
during the next few days. Necrosis is particularly frequent and severe following 
bites by some rattlesnakes, lance-headed vipers (genus Bothrops), Asian pit vipers 
and African vipers (genera Echis and Bitis). When the envenomed tissue is 
contained in a tight fascial compartment such as the pulp space of the fingers or 
toes or the anterior tibial compartment, ischaemia may result. If there is no 
swelling two hours after a viper bite it is usually safe to assume that there has been 
no envenoming. However, fatal envenoming by a few species can occur in the 
absence of local signs (e.g., Crotalus durissus terrificus, C. scutulatus and 
Burmese Russell’s viper).  
  Blood pressure abnormalities are a consistent feature of envenoming by 
Viperidae. Persistent bleeding from fang puncture wounds, venepuncture or 
injection sites, other new and partially healed wounds and post partum, suggests 
that the blood is incoagulable. Spontaneous systemic haemorrhage is most often 
detected in the gums, but may also be seen as epistaxis, haematemesis, cutaneous 
ecchymoses, haemoptysis, subconjunctival, retroperitoneal and intracranial 
haemorrhages. Patients envenomed by the Burmese Russell’s viper may bleed into 
the anterior pituitary gland (Sheehan’s syndrome).  
   Hypotension and shock are common in patients bitten by some of the North 
American rattlesnakes (e.g., C. adamanteus, C. atrox and C. scutulatus), Bothrops, 
Daboia and Vipera species (e.g., V. palaestinae and V. berus). The central venous 
pressure is usually low and the pulse rate rapid, suggesting hypovolaemia, for 
which the usual cause is extravasation of fluid into the bitten limb. Patients 
envenomed by Burmese Russell’s vipers show evidence of generally increased 
vascular permeability. Direct involvement of the heart muscle is suggested by an 
abnormal ECG or cardiac arrhythmia. Patients envenomed by some species of the 
genera Vipera and Bothrops may experience transient recurrent fainting attacks 
associated with features of an autopharmacological or anaphylactic reaction such 
as vomiting, sweating, colic, diarrhoea, shock and angio-oedema, appearing as 
early as five minutes or as late as many hours after the bite.  
   Renal (kidney) failure is the major cause of death in patients envenomed by 
Russell’s vipers who may become oliguric within a few hours of the bite and have 
loin pain suggesting renal ischaemia. Renal failure is also a feature of envenoming 
by Bothrops species and  C. d. terrificus.  
   Neurotoxicity, resembling that seen in patients bitten by Elapidae, is seen 
after bites by C. d. terrificus, Gloydius blomhoffii, Bitis atropos and Sri Lankan D. 
russelii pulchella. There may be evidence of generalized rhabdomyolysis. 
Progression to respiratory or generalized paralysis is unusual.  
Late-onset envenoming 
The patient should be kept under close observation for at leat 24 hours. 
Many species, particularly the Krait and the Hump-nosed pitviper (Joseph et al, 
2006) are known for the length of time it can take for symptoms to manifest. Often 
this can take between 6 to 12 hours. Late onset envenoming is a well documented 
occurrence (Ho et al, 1986) (Warrell et al, 1977) (Reitz, 1989).  
This is also particularly pertinent at the start of the rainy season when 
snakes generally give birth to their young. Juvenile snakes, 8-10 inches long, tend 
to bite the victim lower down on the foot in the hard tissue area, and thus any signs 
of envenomation can take much longer to appear. 
 
 
 
  
 Laboratory Investigations  
The peripheral neutrophil count is raised to 20,000 cells per microlitre or 
more in severely envenomed patients. Initial haemo-concentration, resulting from 
extravasation of plasma  (Crotalus species and Burmese D. russelii), is followed 
by anaemia caused by bleeding or, more rarely, haemolysis. Thrombocytopenia is 
common following bites by pit vipers (e.g., C. rhodostoma, Crotalus viridis 
helleri) and some Viperidae (e.g., Bitis arietans and D. russelii), but is unusual 
after bites by Echis species. A useful test for venom-induced defibrin(ogen)ation is 
the simple whole blood clotting test. A few millilitres of venous blood is placed in 
a new, clean, dry, glass test tube, left undisturbed for 20 minutes at ambient 
temperature, and then tipped to see if it has clotted or not. Incoagulable blood 
indicates systemic envenoming and may be diagnostic of a particular species (for 
example Echis species in Africa). The test should be carried out every 30 minutes 
from admission for three hours and then hourly after that. If incoagulable blood is 
discovered, the 6 hourly cycle will then be adopted to test for the requirement for 
repeat doses of ASV 
 Patients with generalized rhabdomyolysis show a steep rise in serum 
creatine kinase, myoglobin and potassium. Black or brown urine suggests 
generalized rhabdomyolysis or intravascular haemolysis. Concentrations of serum 
enzymes such as creatine phosphokinase and aspartate aminotransferase are 
moderately raised in patients with severe local envenoming, probably because of 
local muscle damage at the site of the bite. Urine should be examined for 
blood/haemoglobin, myoglobin and protein and for microscopic haematuria and 
red cell casts.  
 
Treatment 
First aid  
Patients should be moved to the nearest medical facility as quickly and 
comfortably as possible, avoiding movement of the bitten limb, which should be 
immobilized with a splint or sling.   
Most traditional first-aid methods are potentially harmful(37) and should not 
be used. Local incisions and suction may introduce infection, damage tissues and 
cause persistent bleeding, and are unlikely to remove much venom from the 
wound. The vacuum extractor method is of unproven benefit in human patients 
and could damage soft tissues(40)(41). Potassium permanganate and cryotherapy 
potentiate local necrosis. Electric shock is potentially dangerous and has not 
proved beneficial. Tourniquets and compression bands can cause gangrene(43)(44), 
fibrinolysis, peripheral nerve palsies and increased local envenoming in the 
occluded limb(45).  
The first aid being currently recommended is based around the mnemonic: 
“Do it R.I.G.H.T.” It consists of the following: 
 
R.  Reassure the patient. 70% of all snakebites are from non-     
 venomous species. Only 50% of bites by venomous species        
 actually envenomate the patient 
I   Immobilise in the same way as a fractured limb. Use bandages or cloth to 
hold the splints, not to block the blood supply or apply pressure. Do not 
apply any compression in the form of tight ligatures, they don’t work and 
can be dangerous! 
G. H.  Get to Hospital Immediately. Traditional remedies have NO   
 PROVEN benefit in treating snakebite. 
T Tell the doctor of any systemic symptoms such as ptosis that      
 manifest on the way to hospital. 
 
   The pressure immobilization method involves firm but not tight bandaging of 
the entire bitten limb with a crepe bandage 4-5 m long by 10 cm wide starting over 
the site of the bite and incorporating a splint(38)(39). Pressure immobilization is 
recommended for bites by snakes with neurotoxic venoms (e.g., Elapidae, 
Hydrophiidae) but not when local swelling and necrosis may be a problem (e.g., 
Viperidae)(39).  
   Patients being transported to hospital should be laid on their side to prevent 
aspiration of vomit(42). Persistent vomiting is treated with chlorpromazine by 
intravenous injection (25 to 50 mg for adults, 1 mg/kg body weight for children). 
Syncope, shock, angio-oedema and other anaphylactic (autopharmacological) 
symptoms are treated with 0.1% adrenaline by subcutaneous injection (0.5 ml for 
adults, 0.01 ml/kg body weight for children), and an antihistamine such as 
chlorpheniramine maleate is given by slow intravenous injection (10 mg for 
adults, 0.2 mg/kg body weight for children). Patients with incoagulable blood 
develop large haematomas after intramuscular and subcutaneous injections; the 
intravenous route should be used whenever possible. Respiratory distress and 
cyanosis are treated by establishing an airway, giving oxygen and, if necessary, 
assisted ventilation. If the patient is unconscious and no femoral or carotid pulses 
can be detected, cardiopulmonary resuscitation (CPR) should be started 
immediately.  
   
 
Anti Snake Venom (ASV) 
Anti snake venom (ASV) in India is polyvalent i.e. it is effective against all 
the four common species; Russells viper (Daboia russelii), Common Cobra (Naja 
naja), Common Krait (Bungarus caeruleus) and Saw Scaled viper (Echis 
carinatus). There are no currently available monovalent ASVs primarily because 
there are no objective means of identifying the snake species, in the absence of the 
dead snake. It would be impossible for the physician to determine which type of 
Monovalent ASV to employ in treating the patient. 
 There are known species such as the Hump-nosed pitviper (Hypnale hypnale) 
where polyvalent ASV is known to be ineffective. In addition, there are regionally 
specific species such as Sochurek’s Saw Scaled Viper (Echis carinatus sochureki) 
in Rajasthan, where the effectiveness of polyvalent ASV may be questionable. 
 ASV is produced in both liquid and lyophilised forms(45). There is no 
evidence to suggest which form is more effective and many doctors prefer one or 
the other based purely on personal choice. Liquid ASV requires a reliable cold 
chain and refrigeration and has a 2 year shelf life. Lyophilised ASV, in powder 
form, requires only to be kept cool.  
ASV Administration Criteria 
ASV is a scarce, costly commodity and should only be administered when 
there are definite signs of envenomation. Unbound, free flowing venom, can only 
be neutralised when it is in the bloodstream or tissue fluid. In addition, Anti-Snake 
Venom carries risks of anaphylactic reactions  
ONLY if a Patient develops one or more of the following signs/symptoms 
will ASV be administered (46)
Systemic envenoming 
1. Evidence of coagulopathy: Primarily detected by 20WBCT or  visible 
spontaneous systemic bleeding, gums etc.Further laboratory tests for 
thrombocytopenia, Hb abnormalities, PCV, peripheral smear etc provide 
confirmation, but 20WBCT is paramount. 
2. Evidence of neurotoxicity: ptosis, external ophthalmoplegia, muscle 
paralysis, inability to lift the head etc.  
The above two methods of establishing systemic envenomation are the 
primary determinants. They are simple to carry out, involving bedside tests or 
identification of visible neurological signs and symptoms. In the Indian context 
and in the vast majority of cases, one of these two categories will be the sole 
determinant of whether ASV is administered to a patient. 
 
Severe Current Local envenoming 
1. Severe current, local swelling involving more than half of the bitten limb (in 
the absence of a tourniquet). In the case of severe swelling after bites on the 
digits (toes and especially fingers) after a bite from a known necrotic species. 
2. Rapid extension of swelling (for example beyond the wrist or ankle within a 
few hours of bites on the hands or feet).   Swelling a number of hours old is 
not grounds for giving ASV. 
Purely local swelling, even if accompanied by a bite mark from an apparently 
venomous snake, is not grounds for administering ASV. 
Prevention of ASV Reactions – Prophylactic Regimes 
 Conclusion in respect of prophylactic regimens to prevent anaphylactic 
reactions, is that there is no evidence from good quality randomized clinical trials 
to support their routine use. 
ASV Administration: Dosage 
  The recommended dosage level has been based on published research that 
Russells Viper injects on average 63mg SD 7 mg of venom (Tun Pe, 1986). The 
initial dose should be calculated to neutralise the average dose of venom injected. 
This ensures that the majority of victims should be covered by the initial dose and 
keeps the cost of ASV to acceptable levels. The range of venom injected is 5mg – 
147 mg. This suggests that the total required dose will be between 10 vials to 25 
vials as each vial neutralises 6mg of Russells Viper venom. Starting with 10 vials 
ensures that there is sufficient neutralising power to neutralise the average amount 
of venom injected and during the next 12 hours to neutralise any remaining free 
flowing venom(46). 
NO ASV TEST DOSE MUST BE ADMINISTERED! 
Test doses have been shown to have no predictive value in detecting 
anaphylactoid or late serum reactions and should not be used (Warrell et al 1999). 
These reactions are not IgE mediated but Complement activated. They may also 
pre-sensitise the patient and thereby create greater risk(43)(45). 
ASV is recommended to be administered in the following initial dose:  
 Neurotoxic/ Anti Haemostatic             8-10 Vials 
                                                                                                                                  
N.B. Children receive the same ASV dosage as adults. The ASV is targeted at 
neutralising the venom. Snakes inject the same amount of venom into adults and 
children. 
ASV can be administered in two ways: 
1. Intravenous Injection: reconstituted or liquid ASV is administered by slow 
intravenous injection. (2ml/ minute). Each vial is 10ml of reconstituted 
ASV. 
2. Infusion: liquid or reconstituted ASV is diluted in 5-10ml/kg body weight 
of isotonic saline or glucose. 
All ASV to be administered over 1 hour at constant speed. The patient should be 
closely monitored for 2 hours. Local administration of ASV, near the bite site, has 
been proven to be ineffective, painful and raises the intracompartmental pressure, 
particularly in the digits. It should not be used(42). 
ASV Reactions 
Anaphylaxis is life-threatening, but despite the reluctance in giving ASV 
due to reactions (Kalantri et al, 2005), if the correct protocol is followed, it can be 
effectively treated and dealt with. Anaphylaxis can be rapid onset and can 
deteriorate into a life-threatening emergency very rapidly. Adrenaline should 
always be immediately available. 
The patient should be monitored closely (Peshin et al, 1997) and at the first 
sign of any of the following: 
Urticaria, itching, fever, shaking chills, nausea, vomiting, diarrhoea, abdominal 
cramps, tachycardia, hypotension, bronchospasm and angio-oedema  
 1. ASV will be discontinued 
 2. 0.5mg of 1:1000 adrenaline will be given IM, 
Children are given 0.01mg/kg body weight of adrenaline IM. 
In addition, to provide longer term protection against anaphylactoid reaction, 
100mg of hydrocortisone and an H1 antihistamine, such as Phenimarine maleate 
can be used at 22.5mg IV or Promethazine HCl can be used at 25mg IM, or 10mg 
chlorphenirmarine maleate if available, will be administered IV.  
If after 10 to 15 minutes the patient's condition has not improved or is 
worsening, a second dose of 0.5 mg of adrenalin 1:1000 IM is given(46). This can 
be repeated for a third and final occasion but in the vast majority of reactions, 2 
doses of adrenaline will be sufficient. If there is hypotension or hemodynamic 
instability, IV fluids should be given. 
Once the patient has recovered, the ASV can be restarted slowly for 10-15 
minutes, keeping the patient under close observation. Then the normal drip rate 
should be resumed. 
The IM route for the administration of adrenaline is the option selected, due 
to the rapidity of development in anaphylaxis. Studies have shown that adrenaline 
reaches necessary blood plasma levels in 8 minutes in the IM route, but up to 34 
minutes in the subcutaneous route (American Association, 2003) (Simons, 1998). 
The early use of adrenaline has been selected as a result of study evidence 
suggesting better patient outcome if adrenaline is used early (Sampson et al, 
1992). 
In extremely rare, severe life threatening situations, 0.5mg of 1:10,000 
adrenaline can be given IV. This carries a risk of cardiac arrhythmias however, 
and should only be used if IM adrenaline has been tried and the administration of 
IV adrenaline is in the presence of ventilatory equipment and ICU trained staff. 
It is widely believed that anaphylactoid reactions are under reported 
(McLean-Tooke et al, 2003) 
Late Serum sickness reactions can be easily treated with an oral steroid 
such as prednisolone, adults 5mg 6 hourly, paediatric dose 0.7mg/kg/day. Oral H1 
Antihistamines provide additional symptomatic relief. 
 
Neurotoxic Envenomation 
Neostigmine is an anticholinesterase that prolongs the life of acetylcholine 
and can therefore reverse respiratory failure and neurotoxic symptoms. It is 
particularly effective for post synaptic neurotoxins such as those of the Cobra 
(Watt et al, 1986). There is some doubt over its usefulness against the pre-synaptic 
neurotoxin such as those of the Krait and the Russells Viper (Warrell et al, 1983) 
(Theakston et al, 1990). However it is worth trying in these cases. 
In the case of neurotoxic envenomation the 'Neostigmine Test' will be 
administered, 1.5-2.0 mg of neostigmine IM, together with 0.6mg of atropine IV.  
The patient should be closely observed for 1 hour to determine if the neostigmine 
is effective. 
The following measures are useful objective methods to assess this: 
a) Single breath count 
b) Mm of Iris uncovered (Amount covered by the descending eyelid) 
c) Inter incisor distance (Measured distance between the upper and lower incisors) 
d) Length of time upward gaze can be maintained 
e) FEV 1 or FVC (If available) 
The average blood plasma time for neostigmine is 20 minutes, so by T+30 
minutes any improvement should be visible by an improvement in the measure(46). 
If the victim responds to the neostigmine test then continue with 0.5mg of 
neostigmine IM half hourly plus 0.6mg of atropine IV over an 8 hour period by 
continuous infusion. If there is no improvement in symptoms after one hour, the 
neostigmine should be stopped. 
 
Repeat Doses: Anti Haemostatic 
 In the case of anti haemostatic envenomation, the ASV strategy will be 
based around a six hour time period. When the initial blood test reveals a 
coagulation abnormality, the initial ASV amount will be given over 1 hour.  
No additional ASV will be given until the next Clotting Test is carried out. 
This is due to the inability of the liver to replace clotting factors in under 6 hrs. 
After 6 hours a further coagulation test should be performed and a further 
dose should be administered in the event of continued coagulation disturbance. 
This dose should also be given over 1 hour. CT tests and repeat doses of ASV 
should continue on a 6 hourly pattern until coagulation is restored, unless a species 
is identified as one against which Polyvalent ASV is not effective. 
The repeat dose should be 5-10 vials of ASV i.e. half to one full dose of the 
original amount. The most logical approach is to administer the same dose again, 
as was administered initially.  
 
Repeat Doses: Neurotoxic 
If the initial dose has been unsuccessful in reducing the symptoms or if the 
symptoms have worsened or if the patient has gone into respiratory failure then a 
further dose should be administered, after 1-2 hours. This dose should be the same 
as the initial dose, i.e. if 10 vials were given initially then 10 vials should be 
repeated for a second dose and then ASV is discontinued. 20 vials is the maximum 
dose of ASV that should be given to a neurotoxically enven0omed patient. 
Once the patient is in respiratory failure, has received 20 vials of ASV and 
is supported on a ventilator, ASV therapy should be stopped. Therefore further 
ASV serves no useful purpose. 
 
Surgical Intervention 
Whilst there is undoubtedly a place for a surgical debridement of necrotic 
tissue, the use of fasciotomy is highly questionable. The appearance of (Joseph, 
2003): 
• Pain on passive stretching 
• Pain out of proportion 
• Pulselessness 
a 
nd lead to ischemia. 
asciotomy does not remove or reduce any envenomation. 
 
 
• Pallor 
• Parasthesi
• Paralysis 
with significant swelling in the limb, can lead to the conclusion that the 
intracompartmental pressure is above 40 mm of mercury and thus requires a 
fasciotomy. Fasciotomy is required if the intracompartmental pressure is 
sufficiently high to cause blood vessels to collapse a
F
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Materials and Methods
 
Setting : PCTRC, Government General Hospital & Madras Medical College, 
009 to June 2009 
ance : Obtained from institutional authorities  
 neurological 
s following snake envenomation over a period of six months 
rological 
ns were not included in the study 
Chennai 
Design of study  : Descriptive study 
Duration of study  :  January 2
Ethical Clear
Informed consent : Obtained 
Materials :  
Consecutive patients admitted to PCTRC with one or other
manifestation
commencing from January 2009 formed the materials for the study. 
Exclusion :  
Non venomous snakebites and venomous snakebites with non neu
manifestatio
Pregnant women and persons with any co-existing illness were excluded. 
Methods : 
All patients admitted with neurological manifestations due to snakebite were 
studied . The study was carried out over a six-month-period beginning January 
2009 up to June 2009. The offending snakes were identified either by direct 
examination (when the snake was killed and brought to the hospital) or on the 
basis of eye-witness account. This evidence was further be verified by showing 
photographs of snakes to the eye witness. 
Detailed history was obtained and patients were subjected to neurological 
examination soon after admission. They were regularly assessed hourly for the 
first six hours, 12 hourly for next 72 hours, and then daily until complete recovery. 
Information regarding progression, onset of recovery and results of biochemical 
investigations were  entered in a pre-designed proforma. All patients underwent 
intravenous neostigmine challenge test, whose results were also noted. All patients 
es were done on all the patients and the correlation 
sed. The following 
n and ulnar nerve 
otential ( CMAP) amplitude 
ves 
e action potential (SNAP) 
i)   Recording the change in CMAP amplitude recorded in abductor digiti 
inimi after a train of stimuli at 3 Hz to the ulnar nerve at the wrist 
were treated with lyophilised polyvalent enzyme refined equine immunoglobulins 
(antivenom serum; Haffkine Institute, Mumbai, India) 
Electrophysiologic studi
between clinical and electrophysiologic progression  analy
studies were carried out 
1. Motor nerve conduction studies in media
 i)   measurement of compound muscle action p
 ii)  measurement of F wave latencies 
 iii) calculation of motor conduction velocities 
2. Sensory nerve conduction studies in median and ulnar ner
 i)   measurement of sensory nerv
 ii)  calculation of sensory nerve conduction velocities 
3. Repetitive nerve stimulation tests 
 
m
 
 
 Da
a) 
b) Clinical Features, 
oxicity time, Bite to ASV time,  
electro-physiologic changes, disease course and outcome 
c) Statistics : Simple descriptive statistics 
 
 
 
 
ta Collection : 
Demographic data : Age, sex, domicile, socio economic status 
Clinical data :  Offending snake (wherever feasible), 
Associated toxicities, Bite to Neurot
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 
Magnitude of the problem : 
During the study period a total of 193 patients  were admitted to our centre with 
Snake bite. Of these 193 patients, 30 patients had neurotoxic features either alone 
or associated with other features such as hemotoxicity or local cellulites.  . 
            
Fig 2 Incidence of Neurotoxic Snake 
Bite
Total Snake 
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were 9 fem
                 
GENDER DISTRIBUTION 
Out of the 30 patients, 21 patients were males making up 7
ales making up the remainder 30% of the cases. 
Fig 3 Gender Distribution
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AGE DISTRIBUTION 
Patients were distributed between 17 & 60 years of age with a mean age – 30.35 
and SD – 10.8. 
o. n Years ients S n Age Group i No. of Pat
1            < 10               0 
2           11 – 20               8 
3           21 – 30             10 
4           31 - 40               8 
5           41 – 50               2 
6           51 – 60               2 
7              > 60               0 
 
    Table 2 Age Distribution 
Fig 4 Age Distribution
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OFFENDING SNAKES 
The offending snake was identified by direct examination in just 5 cases and the 
remaining by eye witness account. The offending snakes were identified as due to 
R ls v , Cobra in1
. 
Offending Snake of Percentage 
usse
S. 
iper in 14 (46.7%) 0 (33.3%) and Krait 
Number 
in 6 (20%)  
No Patients 
1 Russels viper             14              47% 
2 Cobra             10              33% 
3 Krait              6              20% 
   
    Table 3   Offending Snakes 
 
 
  
 
 
 
 
 
 
 
Fig 5 Offending Snakes
Russel's Viper
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PRESENTING FEATURES 
Ptosis was the most common presenting feature followed by ophthalmoplegia, 
e demonstrable in 80% of patients. Among them 
2 had associated hemotoxicity. 
 
. 
Presenting Feature 
ency 
limb, neck & respiratory muscles in that order. 
Signs of local envenomation wer
1
S. 
No
Relative 
Frequ
1 Ptosis 90% 
2 Ophthalmoplegia 80% 
3 Cellulitis 80% 
4 Limb Weakness  46.7%
5 Hemotoxicity 40% 
6 Neck&Resp.Muscle 33.3% 
7 Complete paralysis 20% 
8 Renal Failure 10% 
 
   Table 4 Clinical Features 
Fig 6 Clinical Features
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Of these patients with hemotoxicity, 4 patients developed renal failure; 3 of the 4 
patients with renal failure recovered with conservative management and one 
patient needed hemodialysis. 
               
  Fig 7      Renal Failure Fig 7 Renal Failure
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BITE TO NEUROTOXICITY 
Neurological features developed within 30 minutes to 4 hours from the time of 
bite. 20 patients (67%) developed neurological features with in the first hour of 
bite. 4 patients (13%) developed features between 1 and 2 hours, another 4 
patients (13%) between 2 and 3 hours and 2 patients (7%) between 3 and 4 hours. 
 
S. No. Time 
Interval 
No. of Patients 
1 <1 hr 20 
2 1 – 2 hrs 4 
3 2 – 3 hrs 4 
4 3 – 4 hrs 2 
5 > 4 hrs 0 
  
    Table 5    Bite to Neurotoxicity 
 
Fig 8 Onset of Neurotoxicity
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BITE TO ASV TIME 
All the patients who showed features of toxicity needing Anti snake Venom 
received the first dose of Anti snake venom within 6 hours of bite, either at the 
nearest health facility or at our centre,  the mean being 3.7 hours (SD – 1.74). 
  
Fig 9 Bite to ASV Time
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MECHANICAL VENTILATION 
Of the 10 patients who had respiratory muscle weakness, only five required 
mechanical ventilation support on arrival at PCTRC.  
 
 
PROFILE IN PATIENTS WITH CONCOMITANT HEMOTOXICITY 
Among the patients who showed features of Hemotoxicity and Local Cellulitis in 
addition to Neurotoxic features, it was observed that the neurotoxicity was less 
severe than  in those who had associated toxicities. Ptosis (75%) and 
ophthalmoplegia (66.6%) were found to be the most common manifestation. None 
of them developed respiratory manifestations.  
 
Fig 10 Toxicity
N + H + C, 14
N + C, 10
N, 6
N --> Neurotoxicity 
  H --> Haemotoxicity       
C --> Cellulitis   
 
 
 
ELECTROPHYSIOLOGIC CHANGES 
Nerve conduction studies were performed on all 30 patients who showed 
neurotoxic features. Of these 30 patients with neurotoxicity, Nerve conduction 
studies were abnormal in 21 patients. Neurotoxicity was completely reversed in 
the remaining 9 patients by the time NCS was performed.  
The following parameters were studies in the patients  
1. Motor nerve conduction studies in median and ulnar nerve 
 i)   measurement of compound muscle action potential ( CMAP) amplitude 
 ii)  measurement of F wave latencies 
 iii) calculation of motor conduction velocities 
2. Sensory nerve conduction studies in median and ulnar nerves 
 i)   measurement of sensory nerve action potential (SNAP) 
 ii)  calculation of sensory nerve conduction velocities 
3. Repetitive nerve stimulation tests 
 i)   Recording the change in CMAP amplitude recorded in abductor digiti 
minimi after a train of stimuli at 5 Hz to the ulnar nerve at the wrist 
It was observed that CMAP was decreased  in 15 patients (50%) out of the 21 
patients with abnormal NCS. 6 patients (28.6%) out of the 21 showed decremental 
response on RNS and another 6 (28.6%) showed incremental response. 9 patients 
(42.9%) out of the 21 did not show changes on RNS. No changes were observed in 
the F wave latencies, motor & sensory nerve conduction velocities or sensory 
nerve action potential. There was no evidence of delayed sensory or motor 
neuropathy in any of them.  
 
Offending 
Snake 
Normal NCS Decreased 
CMAP 
Decremental 
RNS 
Incremental 
RNS 
Russel’s viper         6          7           0           2 
Cobra         3          4           6           1 
Krait         0          4           0           3 
Total         9          15           6           6 
  
    Table 6  Nerve  Conduction Changes 
 
Fig 11 Neostigmine Response
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The 6 paients who showed a decremental response on RNS were victims of cobra 
bite. However, the 4 other victims of cobra bite failed to show such a response. 
The same six patients bitten by Cobra, who showed decremental response on NCS 
also responded to neostigmine. Thus they correlated with the pattern of post 
synaptic blockade on nerve conduction studies.  
 
DURATION OF STAY 
The over all length of stay in hospital varied from 3 to 22 days with a mean of 7.5 
days (SD – 2.2). 
 
S. No. Duration in 
Days 
No. of Patients 
1 <= 5 days            12 
2 6 – 10 days              6 
3 11 – 15 days              7 
4 16 – 20 days              3 
5 21 – 25 days              3 
  
    Table 7    Duration of stay 
Fig 12 Duration of Stay
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The length of stay (mean - 3.8 days, SD – 1.3) was significantly low among 
neostigmine responsive patients (n=6, 20%) than among non responders (P=0.01).  
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Fig 13 Neostigmine Response
 
  
DEATHS 
There were no deaths during the study period in our study. All the patients who 
went in for respiratory distress requiring mechanical ventilation and hemodialysis 
were successfully treated and recovered without any residual sequelae.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Discussion 
 
  
 At least 421,000 envenomings and 20,000 deaths occur worldwide from 
snakebite annually. These figures may be as high as 1,841,000 envenomings and 
94,000 deaths. On the basis of the estimation that the total number of snakebites is 
two to three times the number of envenomings, it is estimated that 1,200,000–
5,500,000 snakebites may occur globally. The vast majority of the estimated 
burden of snakebite is in South and Southeast Asia, sub-Saharan Africa, and 
Central and South America, In our study, a total of 193 patients  were admitted 
with Snake bite. Of these 193 patients, 30 patients had neurotoxic features either 
alone or associated with other features such as hemotoxicity or local cellulites.  . 
Out of the 30 patients, 21 patients were males making up 70% of the cases. A 
similar finding was observed by Dissenayake et al where males made up 80.4% of 
the cases. There were 9 females making up the remainder 30% of the cases in our 
study. 
 Our patients were distributed between 17 & 60 years of age with a mean age 
– 30.35 and SD – 10.8. In another  study done by Seneviratne U et al, the Mean 
age was found to be 31.9 years with S.D.- 12.1   
 In our study, the offending snake was identified by direct examination in just 
5 cases and the remaining by eye witness account. The offending snakes were 
identified as due to Russels viper in 14 (46.7%), Cobra in10 (33.3%) and Krait in 
6 (20%). As in most cases,  the snake was identified on the basis of eye-witness 
accounts we have not made an attempt to strictly correlate all clinical findings 
with snake species as the above method of identification may not be absolutely 
foolproof, even though inhabitants of the area are very familiar with snakes.  
 In our series, we noticed that Ptosis was the most common presenting feature 
(90% of patients had ptosis) followed by ophthalmoplegia, limb, neck & 
respiratory muscles in that order. In the study by Seneviratne U et al also, the most 
common symptom was drooping of eyelids (85.7%) followed by double vision and 
dysphagia 
 Neurological features developed within 30 minutes to 4 hours from the time 
of bite in all our patients. 20 patients (67%) developed neurological features with 
in the first hour of bite. 4 patients (13%) developed features between 1 and 2 
hours, another 4 patients (13%) between 2 and 3 hours and 2 patients (7%) 
between 3 and 4 hours. In the study done by The Department of Neurology, 
Ratnapura General Hospital, Ratnapura and Base Hospital, Polonnaruwa, Sri 
Lanka, Nine patients (16.1%) developed neurological symptoms within 30 
minutes of the bite whereas 26 (46.4%) reported symptoms from 30 minutes to 
two hours after the bite. The onset of symptoms was from two to four hours after 
the bite in 13 (23.2%). In a minority (8 cases; 14.2%) symptoms occurred after 
four to six hours. 
 All the patients in our study who showed features of toxicity needing Anti 
snake Venom received the first dose of Anti snake venom within 6 hours of bite, 
either at the nearest health facility or at our centre,  the mean being 3.7 hours (SD 
– 1.74). 
 Of the 10 patients who had respiratory muscle weakness, only five required 
mechanical ventilation support on arrival at PCTRC. In the study by Dissenayake 
et al, 10 patients developed respiratory muscle weakness necessitating mechanical 
ventilation. The majority of them were bitten by the krait. Respiratory muscle 
weakness is a potentially fatal manifestation of snake bite. Krait bite is especially 
notorious for rapid development of respiratory failure. However, in our series all 
patients with respiratory failure were successfully managed with the help of 
mechanical ventilation This emphasises the importance of anticipation of this 
complication and timely intervention 
 Snake venom is not a single toxin but a complex mixture of several 
components, including enzymes, polypeptide toxins, non-toxic proteins, 
carbohydrates, metals, lipids, free amino acids, nucleotides and bionic amines(17). 
Neurotoxins of snake venom seem to affect various sites of neuromuscular system. 
Snake venom neurotoxins that bind to acetylcholine receptor sites on the motor 
endplate produce effects similar to those of curare and myasthenia gravis(10). 
Another group of neurotoxins with phospholipase A2 bind presynaptically, 
thereby depressing transmitter release, and are completely resistant to 
anticholinesterases(10)(11)(12). 
 The venom from neurotoxic snake bites can be broadly classified in to a-, b- 
or k- bungarotoxins. While a- and k- bungarotoxins bind to the post synaptic 
nicotinic AchR at the neuromuscular junction and neuronal tissue respectively, b- 
bungaroroxin binds to the the presynaptic terminal blocking the release of acetyl 
choline. These toxins show almost irreversible binding to the receptors, 
competitively inhibiting acetylcholine binding and, consequently, inhibiting the 
acetylcholine-induced electrical response. Snake venom makes use of AChE to 
breakdown any neurotransmitter that might compete with a- or k-bungarotoxin for 
binding to AchRs(10)(11)(12). Myotoxic effects causing rhabdomyolysis has been 
reported. Clinical and electromyographic evidence of myokymia have been 
demonstrated in victims of timber rattlesnake bite (Crotalus horridus horridus) 
suggesting increased peripheral nerve terminal excitability.  
 There is substantial clinical and electrophysiological evidence of defective 
neuromuscular transmission, both pre-synaptic as well as post-synaptic, in 
neurotoxic envenomation. 
 The findings from the nerve conduction studies in our series demonstrate 
both pre and post synaptic pattern of neuromuscular blockade.  
 In our series, it was observed that CMAP was decreased  in 15 patients (50%) 
out of the 21 patients with abnormal NCS. A similar finding was seen in the study 
by Singh et al based on the electrophysiological assessment in patients with 
Bungarus caeruleus bite(8) .  
 Six patients (28.6%) out of the 21 showed decremental response on RNS and 
another 6 (28.6%) showed incremental response. 9 patients (42.9%) out of the 21 
did not show changes on RNS 
 Decremental responses on RNS have been shown in a number of studies in  
envenomation by different snakes, the Papuan taipan snake (Oxyuranus scutellatus 
canni)(9) , Philippine cobra (Naja naja philippinensis)(3), A study from Sri Lanka 
also showed  decremental response to RNS at 20 Hz and 50 Hz.(4) . 
 In the current study 6 patients showed improvement with neurotoxicity 
following neostigmine administration and also a significant decrease in the mean 
length of stay in the hospital. A similar finding has been observed in a previous 
studies on neuroparalytic envenomation(3)(13) while some studies have not proved 
any benefit(14)  
 No changes were observed in the F wave latencies, motor & sensory nerve 
conduction velocities or sensory nerve action potential in our series.  
 The 6 paients who showed a decremental response on RNS were victims of 
cobra bite. However, the 4 other victims of cobra bite failed to show such a 
response. The same six patients bitten by Cobra, who showed decremental 
response on NCS also responded to neostigmine. 
 There was no evidence of delayed sensory or motor neuropathy in any of 
them. A study by Seneviratne et al described a patient with delayed sensory 
neuropathy in a patient following krait bite(16). There have also been reports of 
Guillain Barre syndrome(6) and delayed neuropathy(7)(16) in patients with snake 
bite. However, the current study did not show any findings similar to the ones 
described above. It could be postulated that either direct neurotoxicity or a 
reaction to antivenom may have been responsible for these manifestations found in 
the above studies. Adverse reactions to antivenom appear in two forms; early and 
late. Early reactions tend to occur within 10 to 180 minutes after treatment and 
range from urticaria to anaphylactic shock. Late reactions are immune complex 
diseases and present in the form of serum sickness syndrome usually 5 to 24 days 
after antivenom administration. Both central and peripheral nervous system 
manifestations are seen in association with serum sickness. In view of delayed 
onset, some form of immune-mediated neuropathy is perhaps more likely. 
Autoantibody assays such as anti ganglioside antibodies, immune complex studies, 
serial electrophysiology and nerve biopsy would be useful to elucidate the 
mechanism of delayed neuropathy following neurotoxic envenomation.    
 In the current study, 6 patients showed incremental response on RNS. 
Although the findings may be correlated with the presynaptic pattern of 
neuromuscular blockade, none of the previous studies mentioned above 
demonstrated a similar finding.  
 The over all length of stay in hospital varied from 3 to 22 days with a mean 
of 7.5 days (SD – 2.2). The length of stay (mean - 3.8 days, SD – 1.3) was 
significantly low among neostigmine responsive patients (n=6, 20%) than among 
non responders (P=0.01). A similar finding has been observed in a previous 
studies on neuroparalytic envenomation (Watt G 1986, Pandey AK 1979) while 
some studies have not proved any benefit (Sethi PK 1981) 
 There were no deaths during the study period in our study. All the patients 
who needed mechanical ventilatory support and hemodialysis recovered 
completely with out any residual sequelae. This emphasises the importance of 
anticipation of this complication and timely intervention. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion  
 
 
•  Early recognition and timely administration of Anti snake venom reduces the 
neurological complications. 
•  There was no evidence of delayed motor or sensory neuropathy in any of the 
patients. Neostigmine responsive patients had shorter duration of stay in the 
hospital.   
•  The development of neurological complications is influenced by the nature 
and quantity of envenomation, susceptibility of the individual, post- 
synaptic status, and delay in administration of anti-venin.  
•  In view of the responses on NCS obtained in the current study, further 
laboratory studies are necessary to isolate and characterise the neurotoxic 
components of snake venom, 
•  An understanding of the molecular basis will facilitate our understanding of 
snake venom neurotoxin and its therapeutic implications, both in treatment 
of snake bites and in the development of a novel neuromuscular blocking 
agent.  
•  Further, community based intervention programmes will reduce the 
occurrence of snake bite, morbidity and mortality, and length of stay in 
hospital .  
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PROFORMA 
 
Name    Age   Sex 
 
Address   Occupation 
 
Offending Snake 
 Russels viper 
 Cobra 
 Krait 
 Others 
 Unidentified 
 
Presenting Complaints 
 Ptosis 
 Ophthalmoplegia 
 Cellulitis 
 Limb muscle weakness 
 Bleeding Tendencies 
 Neck & Respiratory muscle weakness 
 Complete Paralysis 
 Renal Failure 
Duration  between bite and onset of Clinical Features 
 
Duration between snake bite and first dose of ASV 
 
Nerve Conduction Changes 
 CMAP 
 MNCV 
 F wave latencies 
 SNAP 
 SNCV 
 RNS 
 
Need for Mechanical Ventilation 
 
Need for Hemodialysis 
 
Duration of stay in the hospital 
 
Outcome 
 
 
 
 
 
 
 
name age sex address species hemo neuro cellulitis renal  ptosis ophthalm neck 
resp 
dis complete
Kannaiyan 60 m sub urban cobra - + + - + + + + + 
Govindan 21 m rural russel's + + + - + + - - - 
priya 20 f rural russel's - + + - + + + + + 
Selvakumar 33 m sub urban cobra - + + - + + - - - 
rahul 19 m rural cobra + + + - + + + + - 
sengammal 50 f rural krait - + - - + + - - - 
Bharathan 40 m rural cobra - + + - + + - - - 
Padmanathan 23 m sub urban russel's + + + - + + - - - 
Pechiappan 25 m sub urban russel's + + + - + + + - - 
latha 40 f sub urban krait - + - - + + - - - 
Vijaykumar 18 m sub urban russel's + + + - + + - - - 
gowri 35 f rural russel's + + + - + + + + - 
Lakshmanan 17 m rural cobra - + + - + + - - - 
amudha 24 f rural krait - + - - + + + + + 
Rangan 60 m sub urban cobra - + + - + + + + + 
Paramasivam 21 m rural russel's + + + - + + - - - 
Prakash 20 m rural russel's - + + - + + + + + 
Chengiammal 33 f sub urban cobra - + + - + + - - - 
Karthik 19 m rural cobra + + + - + + + + - 
Shenbagakumar 50 m rural krait - + - - + + - - - 
Bharathi 40 f rural cobra - + + - + + - - - 
Pachiappan 23 m sub urban russel's + + + - + + - - - 
Chinnakannu 25 m sub urban russel's + + + - + + + - - 
Arunkumar 16 m sub urban krait - + - - + + - - - 
vijayalakshmi 18 f sub urban russel's + + + - + + - - - 
Gokulakannan 35 m rural russel's + + + - + + + + - 
Narayanan 17 m rural cobra - + + - + + - - - 
amudha 24 f rural krait - + - - + + + + + 
Dharshanamoorthy 40 m sub urban russel's + + + - + + - - - 
Dhandapani 18 m sub urban russel's + + + - + + - - - 
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dose neostig surgical cmap1 
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rns 
2 urea creat wbct1 
wbct 
2 
wbct 
3 duration ventilatory dialysis 
n 26 0.9 n n n 22 + - 
n 70 4.2 hi hi hi 7 - + 
n 24 1.2 n n n 4 + - 
n 24 0.8 n n n 10 - - 
n 18 0.8 hi n n 6 - - 
n 18 0.9 n n n 3 - - 
n 38 0.7 n n n 3 - - 
n 42 1.1 hi hi n 5 - - 
n 32 0.8 hi hi n 4 - - 
n 24 0.8 hi hi n 11 - - 
n 44 1 hi n n 3 - - 
n 66 2.8 hi hi hi 12 - - 
n 20 0.9 n n n 3 - - 
n 28 0.8 n n n 12 + - 
n 26 0.9 n n n 22 - - 
n 50 1.5 hi hi hi 6 - - 
n 24 1.2 n n n 4 + - 
n 24 0.8 n n n 7 - - 
n 48 2.1 hi n n 5 - - 
n 18 0.9 n n n 3 - - 
n 38 0.7 n n n 3 - - 
n 42 1.1 hi hi n 5 - - 
n 32 0.8 hi hi n 4 - - 
n 24 0.8 hi hi n 11 - - 
n 44 1 hi n n 3 - - 
n 53 3.1 hi hi hi 12 - - 
n 20 0.9 n n n 3 - - 
n 28 0.8 n n n 12 + - 
n 24 0.8 hi hi n 11 - - 
n 44 1 hi n n 3 - - 
 
